
## Maja Cigrovski Maja Cigrovski Berkovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7540283/publications.pdf

Version: 2024-02-01



Μαία Cigrovski Μαία

#	Article	IF	CITATIONS
1	Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications. Journal of Clinical and Translational Hepatology, 2022, 10, 339-355.	0.7	16
2	Inline Skating as an Additional Activity for Alpine Skiing: The Role of the Outside Leg in Short Turn Performance. International Journal of Environmental Research and Public Health, 2022, 19, 1747.	1.2	2
3	The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis Croatian Medical Journal, 2022, 63, 176-186.	0.2	Ο
4	Assessment of FreeStyle Libre Flash Glucose Monitoring System Implementation in Real Life Clinical Setting: A Prospective Observational Study. Diagnostics, 2021, 11, 305.	1.3	7
5	What Are Kinematic and Kinetic Differences between Short and Parallel Turn in Alpine Skiing?. International Journal of Environmental Research and Public Health, 2021, 18, 3029.	1.2	4
6	How far along are we in revealing the connection between metformin and colorectal cancer?. World Journal of Gastroenterology, 2021, 27, 1362-1368.	1.4	9
7	Fear of hypoglycemia, a game changer during physical activity in type 1 diabetes mellitus patients. World Journal of Diabetes, 2021, 12, 569-577.	1.3	19
8	Effect of COVID-19 on management of type 1 diabetes: Pushing the boundaries of telemedical healthcare. World Journal of Diabetes, 2021, 12, 780-785.	1.3	2
9	Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. World Journal of Diabetes, 2021, 12, 932-938.	1.3	14
10	Shifting perspectives – interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals. World Journal of Hepatology, 2021, 13, 80-93.	0.8	1
11	NAFLD and Physical Exercise: Ready, Steady, Go!. Frontiers in Nutrition, 2021, 8, 734859.	1.6	23
12	Test-Retest Reliability of Unilateral Horizontal Drop Jump in Children. Sustainability, 2021, 13, 12084.	1.6	0
13	Time to the Peak, Shape of the Curve and Combination of These Glucose Response Characteristics During Oral Glucose Tolerance Test as Indicators of Early Beta-cell Dysfunction in Obese Adolescents. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2021, 13, 160-169.	0.4	Ο
14	Time to the Peak, Shape of the Curve and Combination of These Glucose Response Characteristics During Oral Glucose Tolerance Test as Indicators of Early Beta-cell Dysfunction in Obese Adolescents. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2021, 13, 160-169.	0.4	3
15	Minireview: are SGLT2 inhibitors heart savers in diabetes?. Heart Failure Reviews, 2020, 25, 899-905.	1.7	14
16	Hypothyroidism and pregnancy: still a controversial issue. Gynecological Endocrinology, 2020, 36, 776-780.	0.7	5
17	Prevention of cardiac allograft vasculopathy – A new possible indication for SGLT-2 inhibitors?. Medical Hypotheses, 2020, 137, 109594.	0.8	6
18	What is the gut feeling telling us about physical activity in colorectal carcinogenesis?. World Journal of Clinical Cases, 2020, 8, 5844-5851.	0.3	3

Maja Cigrovski Maja

#	Article	IF	CITATIONS
19	Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms. Bosnian Journal of Basic Medical Sciences, 2020, 20, 445-450.	0.6	12
20	Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World Journal of Gastroenterology, 2020, 26, 2740-2757.	1.4	14
21	Sodium-glucose cotransporter 2 inhibitors' mechanisms of action in heart failure. World Journal of Diabetes, 2020, 11, 269-279.	1.3	19
22	How can xsens kinematic suit add to our understanding of a slalom turn. Kinesiology, 2020, 52, 187-195.	0.3	3
23	Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?. World Journal of Diabetes, 2020, 11, 540-552.	1.3	2
24	Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large realâ€world studies. Diabetes, Obesity and Metabolism, 2019, 21, 844-853.	2.2	15
25	Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?. Journal of Clinical and Translational Hepatology, 2019, 7, 1-5.	0.7	16
26	2484-PUB: Association of Gastrin Levels and Parameters of Glucoregulation in Type 2 Diabetes Patients. Diabetes, 2019, 68, .	0.3	0
27	Male sex hormones response after a month-long Himalayas trek in relation to hemoglobin oxygen saturation. Kinesiology, 2018, 50, 157-164.	0.3	0
28	Sport Courage, Worry and Fear in Relation to Success of Alpine Ski Learning. Sports, 2018, 6, 96.	0.7	8
29	Psoriasis Severity—A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome. International Journal of Environmental Research and Public Health, 2018, 15, 1486.	1.2	30
30	The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study. Diabetology and Metabolic Syndrome, 2018, 10, 16.	1.2	5
31	Regional variations in definitions and rates of hypoglycaemia: findings from the global <scp>HAT</scp> observational study of 27 585 people with Type 1 and insulinâ€ŧreated Type 2 diabetes mellitus. Diabetic Medicine, 2018, 35, 1232-1241.	1.2	8
32	Quality of Life in Patients Treated with Insulin Pump Compared with MDI in Croatia. Diabetes, 2018, 67, 2278-PUB.	0.3	0
33	Gastrin—A Potential Predictor of Glucoregulation in Newly Diagnosed Type 2 Diabetes Patients. Diabetes, 2018, 67, 1965-P.	0.3	0
34	Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study. Diabetes Research and Clinical Practice, 2017, 129, 144-147.	1.1	9
35	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 723-732.	13.9	480
36	Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 130, 121-129.	1.1	53

Maja Cigrovski Maja

#	Article	IF	CITATIONS
37	Impact of health policy and practice on finding the best fit for patients with type 2 diabetes after metformin failure: Croatian pilot study. Primary Care Diabetes, 2017, 11, 265-272.	0.9	2
38	Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study. Diabetes Therapy, 2017, 8, 1297-1308.	1.2	13
39	Are We Compensating for the Lack of Physical Activity in Our Diabetic Patients with Treatment Intensification?. Sports, 2017, 5, 58.	0.7	1
40	Gastrin - A Potential Predictor of Response to Incretin Therapy in Diabetes Type 2 Patients. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 17, 297-302.	0.6	1
41	Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis. Acta Diabetologica, 2016, 53, 709-715.	1.2	2
42	Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulinâ€ŧreated type 1 and type 2 diabetes: the global <scp>HAT</scp> study. Diabetes, Obesity and Metabolism, 2016, 18, 907-915.	2.2	203
43	High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Molecular and Cellular Endocrinology, 2016, 425, 61-68.	1.6	18
44	Reliability and Validity of the Inline Skating Skill Test. Journal of Sports Science and Medicine, 2016, 15, 390-396.	0.7	1
45	The Effects of Transition from Bedtime to Morning Glargine Administration in Patients with Poorly Regulated Type 1 Diabetes Mellitus: Croatian Pilot Study. Diabetes Therapy, 2015, 6, 643-648.	1.2	7
46	The influence of ski helmets on sound perception and sound localisation on the ski slope. International Journal of Occupational Medicine and Environmental Health, 2015, 28, 389-94.	0.6	3
47	PO116 PATIENT RESPONSES FOLLOWING HYPOGLYCEMIA IN THE HAT STUDY: A GLOBAL POPULATION-BASED STUDY OF INSULIN-TREATED PATIENTS WITH DIABETES. Diabetes Research and Clinical Practice, 2014, 106, \$104-\$105.	1.1	0
48	New Insights into the Role of Chronic Inflammation and Cytokines in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology, 2014, 99, 75-84.	1.2	28
49	Interleukin 1β Gene Single-Nucleotide Polymorphisms and Susceptibility to Pancreatic Neuroendocrine Tumors. DNA and Cell Biology, 2012, 31, 531-536.	0.9	24
50	n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine, 2012, 367, 309-318.	13.9	810
51	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	13.9	1,426
52	IL-2 â^'330ÂT/G SNP and serum values—potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NETs). Journal of Molecular Medicine, 2010, 88, 423-429.	1.7	31
53	Hypopituitarism caused by pituitary metastasis of supraglottic laryngeal carcinoma: case report. Acta Clinica Croatica, 2010, 49, 347-51.	0.1	2
54	From Cellulite to smooth skin: Is Viagra the new dream cream?. Medical Hypotheses, 2009, 73, 118-119.	0.8	14

Maja Cigrovski Maja

#	Article	IF	CITATIONS
55	Glitazones and skin aging: May they stop the ticking clock?. Medical Hypotheses, 2008, 71, 459-460.	0.8	1
56	IL-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Experimental and Molecular Pathology, 2007, 83, 474-479.	0.9	25
57	A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors. Collegium Antropologicum, 2007, 31, 531-4.	0.1	1
58	TNF-α Promoter Single Nucleotide Polymorphisms in Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology, 2006, 84, 346-352.	1.2	14
59	nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma. Journal of Clinical Pathology, 2004, 57, 1312-1318.	1.0	35